AACR 2023 | Enhancing PD-1 blockade in hepatocellular carcinoma

Ricardo De Azevedo, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on strategies to improve the activity of PD-1 inhibitors in hepatocellular carcinoma. One such strategy involves combination therapies, where capmatinib, a MET inhibitor, has shown have a synergistic effect with PD-1 inhibitors. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.